Genmab to Submit sBLA for Epcoritamab Plus Rituximab in FL
May 2, 2025
Decision to submit based on a positive overall response rate (ORR) (p-value < 0.0001), one of the dual primary endpoints in the Phase 3 EPCORE® FL-1
Decision to submit based on a positive overall response rate (ORR) (p-value < 0.0001), one of the dual primary endpoints in the Phase 3 EPCORE® FL-1
Fuel up with free Health Tech Insights